ZHONGSHENGYAOYE(SZ:002317)2026-01-23 09:22Group 1: Partnership and Financial Aspects - The collaboration between Zhongsheng Ruichuang and Qilu Pharmaceutical involves a licensing agreement for the RAY1225 injection, allowing Qilu to produce and commercialize the product in China, while Zhongsheng retains all intellectual property rights [1][3]. - Zhongsheng will receive an upfront payment of RMB 200 million and may earn up to RMB 800 million in milestone payments based on development and sales achievements [3]. - After the first commercial sale of the licensed product, Zhongsheng is entitled to a double-digit percentage of net sales in the licensed regions [3]. Group 2: Innovation and Drug Development - Zhongsheng focuses on innovative drug development, particularly in metabolic diseases and respiratory diseases, with two projects already approved for market and several others in clinical trials [6][8]. - The RAY1225 injection is a novel dual-agonist peptide drug with potential for bi-weekly administration, targeting type 2 diabetes and obesity, currently undergoing multiple Phase III clinical trials [10][11]. - The company is also developing ZSP1601, a treatment for metabolic dysfunction-related fatty liver disease (MASH), which has shown promising results in early clinical trials [6][12]. Group 3: Market Strategy and Future Outlook - The partnership aims to leverage both companies' strengths to enhance commercialization efficiency and market reach, while reducing operational costs related to production and marketing [3]. - Zhongsheng remains committed to exploring overseas markets and does not intend to limit its international expansion despite the current focus on the Chinese market [4]. - The company is actively pursuing innovative solutions to meet unmet clinical needs, particularly in the treatment of MASH, which currently lacks approved therapies in China [12].